483
R. Doyle Stulting, MDFDA 483 - R. Doyle Stulting, MD - August 18, 2023
Record Details
An FDA inspection of R. Doyle Stulting, MD, a sponsor-investigator, revealed significant deficiencies in clinical trial conduct. Observations included the failure to report numerous non-serious adverse events to the sponsor, failure to submit two annual reports to the FDA, and failure to obtain IRB approval for a change in principal investigator prior to implementation. These findings indicate a lack of adherence to regulatory requirements for clinical research.
Open in Dashboard
ID · affed33f-6f4d-4405-8a36-b8e3092b11a8